glp-1 and cardiovascular benefits disease continuum-GLP-1 action. Adapted from [46] GLP-1 Receptor Agonists for the
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 68.Traish A.M., Toselli P., Jeong S.J., Kim N.N
![glp-1 and cardiovascular benefits disease continuum-GLP-1 action. Adapted from [46] GLP-1 Receptor Agonists for the](https://www.ahajournals.org/cms/10.1161/CIRCULATIONAHA.122.059595/asset/ad09f9fb-0bf4-4c02-8c15-fe4df1f5a441/assets/graphic/circulationaha.122.059595.fig01.jpg)
These findings are aligned with prior research, including the randomized study by Kahal et al
![glp-1 and cardiovascular benefits disease continuum-GLP-1 action. Adapted from [46] GLP-1 Receptor Agonists for the](https://cdn-ilbbpbp.nitrocdn.com/ojRiPrKQZiUfKYhPZsusFRJPrNGhbJKT/assets/images/optimized/rev-d503bc9/www.vitalityhrt.com/wp-content/uploads/2024/12/GLP_INFOGRAPHIC_RV_MALE-1024x1024.png)
doi 10.1038/nutd.2012.29 106 ZiadlouRPandianGNHafnerJAkdisCAStinglGMaverakisEet al
![glp-1 and cardiovascular benefits disease continuum-GLP-1 action. Adapted from [46] GLP-1 Receptor Agonists for the](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffd4/12904707/4fa38c7b0690/jci-136-194748-g202.jpg)
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
![glp-1 and cardiovascular benefits disease continuum-GLP-1 action. Adapted from [46] GLP-1 Receptor Agonists for the](https://www.mdpi.com/biomedicines/biomedicines-13-02595/article_deploy/html/images/biomedicines-13-02595-g005-550.jpg)
[DOI] [PMC free article] [PubMed] [Google Scholar] 92.Wang B, Su Z, Kuang M, Luo Y, Xu M, Sun M, et al
![glp-1 and cardiovascular benefits disease continuum-GLP-1 action. Adapted from [46] GLP-1 Receptor Agonists for the](https://substackcdn.com/image/fetch/$s_!3qSJ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa7155415-bd4a-4361-b564-cf49c9e71789_1456x1787.webp)